Endocrine and Metabolic Science最新文献

{"title":"Harnessing nanoscale innovations for enhanced healing of diabetic foot ulcers","authors":"Marwan Al-Raeei","doi":"10.1016/j.endmts.2024.100210","DOIUrl":"10.1016/j.endmts.2024.100210","url":null,"abstract":"<div><div>In this article, we explore the transformative potential of nanomaterials in managing diabetic foot ulcers (DFUs), a significant complication affecting millions of individuals globally. These chronic wounds pose substantial challenges in diabetes care, often leading to severe infections and amputations. We emphasize that traditional treatment modalities are insufficient, thereby necessitating innovative approaches. Nanomaterials, characterized by unique physicochemical properties at the nanoscale, enhance biological interactions, facilitating accelerated healing, and targeted drug delivery. We discuss various applications of nanomaterials, from their intrinsic antimicrobial capabilities—exemplified by silver nanoparticles—to their role in promoting cell proliferation and migration critical for effective tissue repair. Furthermore, we highlight their capacity for controlled drug release and improved oxygen supply, both vital for optimal wound healing. This comprehensive review delineates the steps required for integrating nanomaterials into clinical practice, stressing the importance of thorough research, formulation, regulatory approval, and personalized treatment strategies. By leveraging these advanced materials, we assert that significant advancements in DFU management can be achieved, improving patient outcomes and quality of life. Our findings underscore the necessity for ongoing research aimed at optimizing the application of nanomaterials in wound care, thereby paving the way for innovative, evidence-based practices that address the complex challenges inherent in diabetic foot ulcer treatment.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100210"},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic and meta-analyses of diabetic retinopathy and its care-related predictors after diabetic mellitus treatment initiation in Ethiopia","authors":"Aboma Motuma ,&nbsp;Abdi Birhanu ,&nbsp;Lemma Demissie Regassa ,&nbsp;Sina Tolera ,&nbsp;Alemayehu Deressa ,&nbsp;Usmael Jibro ,&nbsp;Mulugeta Gamachu ,&nbsp;Moti Tolera ,&nbsp;Adera Debella ,&nbsp;Bikila Balis ,&nbsp;Addis Eyeberu ,&nbsp;Fethia Mohammed ,&nbsp;Ibsa Mussa","doi":"10.1016/j.endmts.2024.100209","DOIUrl":"10.1016/j.endmts.2024.100209","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM) that affects the blood vessels of the retina and cause vision loss and blindness. DR is a major public health problem worldwide, especially in low-and middle-income countries where access to screening and treatment is limited. Although Ethiopia has implemented a strategic plan targeting DM care improvement to reduce complications from 2020 to 2025, retinopathy is a severe complication among DM patients. Therefore, this study aimed to assess diabetic retinopathy among DM patients after treatment initiation in Ethiopia from 2020/2021 to 2024/2025 after the strategy was implemented.</div></div><div><h3>Method</h3><div>Using the preferred reporting items for systematic reviews and meta-analysis guidelines, we systematically reviewed and meta-analyzed articles from Scholar, PubMed, Excerpta Medical Database (EMBASE), Cochrane Library, and MESH Medline. The data were extracted using Microsoft Excel and analyzed using STATA version 17. The pooled risk of new diabetic retinopathy among diabetes patients who started DM treatment was estimated. To minimize the effect of heterogeneity, subgroup analysis was performed by geographical region and year of publication (between 2020 and 2023). Publication bias was detected using a funnel plot, with P &lt; 0.05 assumed to indicate potential publication bias. The I² test was used to assess the heterogeneity of the studies.</div></div><div><h3>Results</h3><div>The pooled risk of diabetic retinopathy among treated DM patients was 25.43% (95% CI: 18.1, 32.7) from 2020 to 2023. The incidence of DR was 28.6% in the South Nation, Nationalities, and People (SNNPs) region, followed by Oromia (31.35%) and Amhara (22.93%). Care-related factors such as receiving a combination of DM medication (AOR=0.62, 95% CI: 0.47–0.82, n=3), having good glycemic control (AOR=0.24, 95% CI; 0.17–0.33, n=4), and comorbidities with hypertension (AOR=1.39, 95% CI; 1.17–1.87, n=4) were predictors of diabetic retinopathy development among DM patients at follow-up.</div></div><div><h3>Conclusion</h3><div>Even if the studies could not be combined due to high heterogeneity, they demonstrated that diabetic complications, particularly DR, are still high after starting treatment among DM patients in Ethiopia. Care-related factors such as treatment modalities, glycemic control levels, and comorbidities with hypertension should be appropriately screened and managed to reduce the burden of DR among DM patients receiving follow-up care in Ethiopia. Moreover, Ethiopia should evaluate the already set plan implementation status to achieve the target set by 2025.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100209"},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CtBP: A mediator of a metabolic switch from homeostasis to carcinogenesis","authors":"Saumya Shukla,&nbsp;Raghvendra Singh","doi":"10.1016/j.endmts.2024.100208","DOIUrl":"10.1016/j.endmts.2024.100208","url":null,"abstract":"<div><div>The dimeric form of C-terminus binding protein (CtBP), which is responsible for a balanced transcription rate of genes involved in the homeostatic processes, is a global corepressor. CtBP dimerization and formation of the CtBP corepressor complex require NADH. Under a normal NADH/NAD+ ratio, CtBP is in the dimeric form while, when NADH/NAD+ decreases, it converts into a monomeric form. The monomeric form of CtBP inhibits histone acetyltransferase p300, which plays an important role in the packaging of newly replicated and repaired DNA into chromatin by acetylating the histone H3 core domain lysine 56 (H3K56). Further, by inhibiting p300, the monomeric form of CtBP inhibits NFκB, which plays an important role in the innate immune response toward neoantigens. Furthermore, NFκB causes the transcription of IL-6, which is important in the resolution of the innate immune response. Moreover, by inhibiting p300, the monomeric CtBP inhibits p53, the guardian of the genome. Thus, by inhibiting p300, the monomeric form of CtBP may be involved in carcinogenesis when NADH/NAD+ ratio decreases. In contrast, hypoxia increases the NADH/NAD+ ratio, generating the dimeric form of CtBP and relieving the inhibition of p300 by the monomeric CtBP. The higher NADH/NAD+ ratio and p300 activity under hypoxia mask the instability of cancer cells, confer invasive properties, cause COX-2 expression, increase the transactivation activity of the hypoxia-inducible factor (HIF), and cause drug resistance through NFκB. Thus, p300, regulated by NADH/NAD+ ratio through CtBP, works as a double-edged sword in cancer initiation and progression, respectively.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100208"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial dynamics, biogenesis, mitophagy and oxidative stress in gestational obesity: A review","authors":"Karenth Milena Rodríguez-Córdoba ,&nbsp;Sofia Agreda Soto ,&nbsp;Jenniffer Alejandra Castellanos Garzón ,&nbsp;Maria Carolina Pustovrh-Ramos","doi":"10.1016/j.endmts.2024.100205","DOIUrl":"10.1016/j.endmts.2024.100205","url":null,"abstract":"<div><div>Maternal obesity is a major global health problem with serious implications for maternal and fetal well-being. It creates a lipotoxic environment in the placenta, characterised by increased inflammation, oxidative stress and disturbances in mitochondrial dynamics and biogenesis. The aim of this review is to explore the intricate interactions between mitochondrial dynamics, biogenesis and mitophagy in the context of gestational obesity. Adverse mitochondrial adaptations associated with maternal obesity contribute to placental dysfunction, impairing its ability to support healthy fetal development and increasing the risk of metabolic, cardiovascular and neurodegenerative diseases in the offspring. In addition, mitochondrial dysfunction exacerbates oxidative stress, creating a vicious cycle that further impairs cellular processes. The findings highlight the urgent need for targeted interventions to improve mitochondrial function and placental health, ultimately reducing long-term health risks for both mother and child.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"17 ","pages":"Article 100205"},"PeriodicalIF":0.0,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative study between metformin and insulin on biochemical variables in diabetic patients","authors":"Maha Elttayef Jasim ,&nbsp;Noor Essam Abdul-Razzaq","doi":"10.1016/j.endmts.2024.100206","DOIUrl":"10.1016/j.endmts.2024.100206","url":null,"abstract":"<div><div>Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels due to inadequate insulin production or inefficient use of insulin by the body's cells. It poses significant health risks, including cardiovascular disease and kidney damage, affecting millions worldwide. Management involves careful monitoring of blood glucose levels, lifestyle modifications, and sometimes insulin therapy to maintain optimal health.so Metformin is a widely prescribed oral medication used to manage type 2 diabetes by improving insulin sensitivity.</div><div>The study was conducted in the period from February to March 2023, where a blood sample was collected from males aged from 30 to 50 years. The samples were divided into 15 healthy people as control, 12 samples with diabetes type 2, 12 samples with diabetes type 2 who are treated with metformin, and 12 samples with diabetes type 2 who are treated with insulin injections. The samples were separated in a centrifuge at 4000 rpm, then divided to 10 fractions and stored in the freezer until biochemical tests were performed for the study.</div><div>The results showed A significant increase at Glucose and HbA1C in all groups compared with control. So total cholesterol and low density lipoprotein decrease in diabetic and treatment with insulin injections compared all groups, triglycerides and very low density lipoprotein increase in all diabetic groups compared with control. Alanin trans aminase showed decrease value in diabetic group and treatment with insulin injections compared with all groups but aspartate trans aminase showed result opposite.</div></div><div><h3>Aim of study</h3><div>Since diabetes is a chronic disease, it is necessary to know the effects of the most famous treatments taken by diabetics, which are metformin and insulin, on the lipid profile and liver and kidney functions.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"16 ","pages":"Article 100206"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of thyroid dysfunction among pregnant women in the horn of Africa: A systematic review and Meta-analysis","authors":"Marye Nigatie ,&nbsp;Getinet Kumie ,&nbsp;Abdu Jemal ,&nbsp;Solomon Gedfie ,&nbsp;Woldeteklehaymanot Kassahun ,&nbsp;Muluken Gashaw ,&nbsp;Agenagnew Ashagre ,&nbsp;Tadesse Misganaw ,&nbsp;Wagaw Abebe ,&nbsp;Ermias Getachew ,&nbsp;Selamyhun Tadesse ,&nbsp;Zelalem Dejazmach ,&nbsp;Sisay Ayana ,&nbsp;Yalewayker Gashaw ,&nbsp;Zelalem Asmare ,&nbsp;Assefa Sisay ,&nbsp;Atitegeb Abera ,&nbsp;Biruk Beletew Abate ,&nbsp;Melese Abate Reta","doi":"10.1016/j.endmts.2024.100200","DOIUrl":"10.1016/j.endmts.2024.100200","url":null,"abstract":"<div><h3>Background</h3><div>Thyroid dysfunction ranks among the most prevalent endocrine disorders. This disorder during pregnancy has been linked to adverse effects on both the mother and the baby. However, there is a scarcity of data and inconsistent documentation regarding thyroid issues in pregnant women in low-income nations.</div></div><div><h3>Objective</h3><div>The aim of this systematic review and meta-analysis was to determine the general prevalence of thyroid disorders in pregnant women.</div></div><div><h3>Methods</h3><div>To identify relevant studies, a comprehensive search was conducted across Scopus, PubMed, Science Direct databases, and Google Scholar and repository registers from January 1, 2000 to December 31, 2023. Ten pertinent publications were chosen for the final meta-analysis. Relevant data was extracted using Microsoft Excel and analyzed using STATA software version 17, employing a random-effect model. Sensitivity analysis was conducted to evaluate each study's impact on the outcome, and Egger's test was utilized to detect publication bias. A trim-and-fill analysis was executed to adjust for bias in the effect estimate. Heterogeneity across studies was assessed using Cochran's Q statistic and I² statistics. Subgroup analysis was carried by study design, country and publication year.</div></div><div><h3>Results</h3><div>In this systematic review and meta-analysis, the prevalence of thyroid dysfunction among 2538 pregnant women was 12.0 % (95 % CI: 8.00 %–17.00 %). To account for the significant heterogeneity observed, a random effect model was utilized. Specifically, the prevalence of hypothyroidism in pregnant women was determined to be 10.00 % (95 % CI: 4.00–16.00 %) with a high level of heterogeneity (I² = 94.27 %, <em>p</em> &lt; 0.001). Notably, the sensitivity analysis conducted did not reveal any substantial impact on the overall pooled prevalence of thyroid dysfunction.</div></div><div><h3>Conclusion</h3><div>The meta-analysis revealed a significantly higher rate of thyroid disorders among pregnant women compared to global estimates. To assess the effects of treating thyroid conditions on pregnancy outcomes and inform clinical decisions, it is recommended to implement cost-effective thyroid-stimulating hormone screening during pregnancy.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"16 ","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet activation and inflammation in transgender women using hormone therapy","authors":"Lieve Mees van Zijverden ,&nbsp;Moya Henriëtte Schutte ,&nbsp;Marieke Tebbens ,&nbsp;Milou Cecilia Madsen ,&nbsp;Jeske Joanna Katarina van Diemen ,&nbsp;Chantal Maria Wiepjes ,&nbsp;Martin den Heijer ,&nbsp;Abel Thijs","doi":"10.1016/j.endmts.2024.100201","DOIUrl":"10.1016/j.endmts.2024.100201","url":null,"abstract":"<div><h3>Objective</h3><div>The pathophysiological process behind the increased risk of cardiovascular disease (CVD) in transgender women remains to be elucidated. This exploratory study aimed to investigate whether changes in platelet activation and inflammation after the start of feminizing gender-affirming hormone therapy (GAHT) could be a contributing mechanism.</div></div><div><h3>Design</h3><div>Longitudinal cohort study.</div></div><div><h3>Methods</h3><div>Venous blood was collected from 17 transgender women at 0, 12 and 52 weeks after GAHT initiation, consisting of estradiol and testosterone suppression. Platelet activation markers plasma thromboxane B2, Closure Time, CD63, CD62p, platelet-leukocyte complexes and immature platelet fraction were measured. CRP and 11 cytokines were measured as inflammation markers.</div></div><div><h3>Results</h3><div>CD63, CD62p and platelet-leukocyte complexes tended to increase after 12 weeks of GAHT. After 52 weeks, all platelet activation markers showed anti-aggregatory changes. Eight out twelve inflammation markers exhibited a decreasing tendency at week 12. Equivalently, after 52 weeks, eight inflammation markers tended to decrease, seven of which had also exhibited a decrease at week 12.</div></div><div><h3>Conclusions</h3><div>The collective findings suggest that platelet activation fluctuates during feminizing GAHT, exhibiting an initial increase followed by a decrease. Additionally, inflammation markers tend to decrease. Within the scope of this study, we could not identify GAHT induced platelet activation as a definite contributing factor in the increased risk of CVD in transgender women. Studies with larger numbers of participants and longer follow-up duration are needed to further investigate the effect of feminizing gender-affirming hormone therapy on platelet activation and inflammation.</div></div><div><h3>Trial registration</h3><div>EudraCT #2017-003072-31.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"16 ","pages":"Article 100201"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142532009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute and prolonged ketosis lower serum IGF-I levels in human subjects","authors":"Mads Svart ,&nbsp;Alisa D. Kjaergaard ,&nbsp;Thien Vinh Luong ,&nbsp;Lars C. Gormsen ,&nbsp;Niels Møller ,&nbsp;Jens Otto L. Jørgensen ,&nbsp;Esben Søndergaard","doi":"10.1016/j.endmts.2024.100207","DOIUrl":"10.1016/j.endmts.2024.100207","url":null,"abstract":"<div><h3>Objective</h3><div>Metabolic health and longevity are influenced by numerous factors including the growth hormone (GH) – insulin-like growth factor I (IGF<img>I) axis and ketone bodies (KB). However, data on the impact of KB exposure on GH and IGF-I levels are few.</div></div><div><h3>Design and patients</h3><div>To investigate the effect of acute and chronic KB exposure on GH and IGF-I levels in human subjects. GH and IGF-I levels were measured in three human studies: i) After a single oral ingestion of KB (36.5 g of Na-D/L-βOHB) vs. placebo in six healthy individuals; ii): after a three-week isocaloric ketogenic diet (KD) compared to a standard diet (SD) in 11 overweight individuals; and iii) in a genetic predisposition study using the specific genetic variants in the SCOT gene (rs7712274 and rs7728482), which is associated with ketonuria.</div></div><div><h3>Results</h3><div>A single oral KB ingestion significantly lowered serum IGF-I with 33 ng/ml (KB ingestion) vs 15 ng/ml (placebo), <em>P</em> = 0.01. Ketogenic diet significantly lowered serum IGF-I levels 111 ng/ml (KD) vs 125 ng/ml (SD), P = 0.01 in combination with a two-fold increase in serum GH 0.9 ng/ml to 1.8 ng/ml (KD) compared to 0.9 ng/ml to 0.4 ng/ml (SD), <em>P</em> = 0.03. Individuals with genetic predisposition to ketonuria had lower levels of IGF-I (β = −0.0068, SE = 0.0029, <em>P</em> = 0.02).</div></div><div><h3>Conclusions</h3><div>KB exposure is associated with reduced serum IGF-I levels in the presence of non-suppressed or elevated GH levels. This observation points to a suppressive effect of KB on hepatic IGF-I production. The association between genetic predisposition to ketonuria and increased body size is unexpected and deserves further investigations.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"16 ","pages":"Article 100207"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and temporal trends of anemia in patients with thyroid disease: 1999–2018 NHANES","authors":"Juan Liu,&nbsp;Xin Wang,&nbsp;Liping Huang,&nbsp;Yanqiu Li,&nbsp;Mingliang Chen","doi":"10.1016/j.endmts.2024.100198","DOIUrl":"10.1016/j.endmts.2024.100198","url":null,"abstract":"<div><h3>Background</h3><div>Anemia and thyroid disease, both prevalent health conditions, often co-occur and may be easily overlooked, collectively imposing a significant burden on society. This study specifically investigated the prevalence and temporal trends of anemia among individuals with thyroid disease in the US population, shedding light on a critical intersection in public health.</div></div><div><h3>Methods</h3><div>Utilizing National Health and Nutrition Examination data from 10 survey cycles (1999<strong>–</strong>2018), this study included participants aged 20<strong>–</strong>85 years who self-reported a diagnosis of thyroid disease. Anemia was defined with a cutoff of 12 g/dL for women and 13 g/dL for men. The chi-square test compared prevalence across different categories and survey cycles. Data analysis employed R 4.3.2, with <em>P</em> &lt; 0.05 considered statistically significant.</div></div><div><h3>Results</h3><div>The median hemoglobin level among all individuals with thyroid disease was 13.6 g/dL. The overall prevalence of anemia among the US thyroid disease patients was 12.00 % (95 % CI: 10.96–13.09). A noteworthy upward trend in the prevalence of anemia among thyroid disease patients occurred during 1999<strong>–</strong>2008 (9.58 %, 95 % CI: 8.14<strong>–</strong>11.18) and 2009<strong>–</strong>2018 (13.68 %, 95 % CI: 12.26<strong>–</strong>15.21). Anemia incidence in individuals with thyroid disease was higher in females (9.05 %, 95 % CI: 8.14<strong>–</strong>10.02), the elderly population (7.98 %, 95 % CI: 7.12<strong>–</strong>8.91), individuals living alone (5.96 %, 95 % CI: 5.21<strong>–</strong>6.77), those with high body mass index (5.38 %, 95 % CI: 4.67<strong>–</strong>6.17), and non-Hispanic Whites (5.33 %, 95 % CI: 4.62<strong>–</strong>6.11).</div></div><div><h3>Conclusions</h3><div>The prevalence of anemia in the US population with thyroid disease was 12 %, indicating an increase over the past few decades.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"16 ","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term diabetic hyperglycaemia modifies social behaviour in rats","authors":"Justine Renaud ,&nbsp;Alexandre Clouet ,&nbsp;Giulia Costa ,&nbsp;Jimmy Beaulieu ,&nbsp;Domenico Sergi ,&nbsp;Maria-Grazia Martinoli","doi":"10.1016/j.endmts.2024.100197","DOIUrl":"10.1016/j.endmts.2024.100197","url":null,"abstract":"<div><div>Diabetes is a known risk factor for cognitive decline and mood disorders. However, the effects of long-term diabetic hyperglycaemia on the various dimensions of social behaviours, such as play or aggression, remains to be fully elucidated. In this study, we evaluated the social behaviour in a nicotinamide-streptozotocin rat model of long-term diabetic hyperglycaemia, in the absence of glucose-lowering treatments. Five months following induction of hyperglycaemia, we scored affiliative/exploratory or aggressive social interactions between pairs of unacquainted rats in a neutral arena. Our results demonstrate alterations in the behaviour of long-term diabetic rats faced with social novelties. Specifically, diabetic hyperglycaemic rats engaged in hyper-sociable and hyper-aggressive encounters. Interestingly, social interactivity was not associated with the degree of hyperglycaemia in affiliative/exploratory or in aggressive social interactions, in our long-term diabetic rat model. Altogether, our data suggest a lack of social appropriateness in long-term diabetic hyperglycaemic rats which is independent of the degree of hyperglycaemia. These findings support the importance of a tight glycaemic control in the management of diabetes at every stage of the disease and enlighten the importance of impaired glycaemic control as a novel metabolic player impacting the neural networks of social behaviours.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"16 ","pages":"Article 100197"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142434053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}